Product category:
Contract research
News Release from: R5 Pharmaceuticals
Edited by the Laboratorytalk Editorial
Team on 26 March 2007
Key role in drug development for pharma
industry
R5 Pharmaceuticals announces the launch of its comprehensive range of contract services in drug development for the pharma and biotech industry
R5 Pharmaceuticals, based on the BioCity campus, Nottingham, says it offers an efficient and integrated approach to pharmaceutical development, from drug formulation and delivery technology through to full scale manufacture Led by a uniquely experienced management team, R5 Pharmaceuticals provides appropriate solutions for the development of safe and effective pharmaceutical materials to be used in clinical studies
This article was originally published on Laboratorytalk on 24 Feb 2003 at 8.00am (UK)
Related stories
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
Acquisition creates global CRO
Advanced Clinical Sciences becomes a global player in clinical research with the takeover of a Swiss CRO called CRC
R5 is also applying its expertise to new and rapidly evolving areas such as paediatric products and nutraceuticals, which are coming under increasing pharmaceutical regulation.
Paul Titley, CEO, R5 Pharmaceuticals comments: "The importance of formulation in the drug development process should never be underestimated.
"From the identification of initial targets and lead compounds to the creation of a tangible product with therapeutic benefit, verified as safe to use in humans, the early stages of drug development present a formidable challenge.
Further reading
Achema 2003 - world forum for process industries
27th International exhibition and congress on chemical engineering, environmental protection, and biotechnology
Achema rises to market challenge
Despite the economic uncertainty of the time, the mammoth process industries event in Frankfurt this May will be almost as big as the last record-breaking event, in 2000
"R5 Pharmaceuticals has the capability to optimise the potential of new drugs in development so that, ultimately, patients benefit from new medicines that are safe and effective.
"Further to this, it is clear that each stage requires thorough and efficient methodology, as well as high quality facilities and a strong team".
The facilities include one of the very few cleanrooms in Europe, enabling the highest level of sterile product development.
This is absolutely essential in early clinical development, to ensure that the final product will provide therapeutic benefits for patients, while maintaining its safety.
R5 Pharmaceuticals is based in BioCity Nottingham, a healthcare and bioscience innovation and incubation centre that was made possible by a huge donation of laboratory and office buildings and equipment from BASF to Nottingham Trent University in 2001.
Through the use of a pre-existing, purpose-built building, along with high spec, reclaimed equipment, R5 Pharmaceuticals made a saving of nearly £5 million pounds in start-up costs, overcoming formidable hurdles for a start-up venture and enabling the company to offer the highest quality services from its inception.
Titley adds: "We are delighted to be leading such innovative science through the use of cutting edge facilities and procedures.
"With increased regulation in clinical studies, it has become more important than ever to ensure the products used are efficacious but are also proven to have high patient acceptability.
"The facilities at R5 only allow for sterile manufacturing, but also ensure that each stage of development is carried out meticulously, converting interesting molecules into complex, effective and safe medicines.".
• R5 Pharmaceuticals: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
